Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus

Hyperuricaemia is associated with an increased risk of gout, kidney stones and cardiovascular disease. The present post hoc analysis of pooled data from four placebo‐controlled phase III studies assessed the effect of canagliflozin, a sodium‐glucose co‐transporter 2 inhibitor, on serum uric acid lev...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes, obesity & metabolism obesity & metabolism, 2015-04, Vol.17 (4), p.426-429
Hauptverfasser:	Davies, M. J., Trujillo, A., Vijapurkar, U., Damaraju, C. V., Meininger, G.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antidiabetics Calculi canagliflozin Canagliflozin - administration & dosage Canagliflozin - adverse effects Canagliflozin - therapeutic use Cardiovascular diseases Cohort Studies Diabetes diabetes complications Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Dose-Response Relationship, Drug Down-Regulation drug mechanism Drug Therapy, Combination - adverse effects Drugs Female Glucose transporter Gout Gout - epidemiology Gout - etiology Gout - prevention & control Humans Hyperuricemia Hyperuricemia - complications Hyperuricemia - physiopathology Hyperuricemia - prevention & control Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - adverse effects Hypoglycemic Agents - therapeutic use Incidence Kidney Calculi - epidemiology Kidney Calculi - etiology Kidney Calculi - prevention & control Kidney stones Kidneys Male Middle Aged Nephrolithiasis Placebos Research Letter Research Letters Rheumatism Risk SGLT2 inhibitor Sodium-Glucose Transporter 2 - antagonists & inhibitors type 2 diabetes Uric acid Uric Acid - blood
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!